Compare Neurocrine Biosciences Inc (NBIX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.66 (market cap $16.46B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.51. The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SPHD | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $185.50 | $53.55 |
52-Week Low | $123.10 | $46.96 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
SPHD trades at $52.405, showing minimal daily movement with a slight decline of 0.01%. The ETF maintains a bullish technical signal from moving averages, while oscillators indicate neutrality. Recent news highlights its focus on high dividends and low volatility, appealing to income investors seeking stability amid market swings. Dividend payments are scheduled for 2026, reinforcing its income-generating strategy.
The outlook for SPHD is stable, supported by its dividend yield and low-volatility approach, attracting retirees and risk-averse investors. Key risks include interest rate sensitivity and broader market downturns, which could impact dividend sustainability and NAV. Analyst sentiment remains positive due to consistent income appeal in volatile environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
